These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7783134)

  • 1. Ribozymes as human therapeutic agents.
    Christoffersen RE; Marr JJ
    J Med Chem; 1995 Jun; 38(12):2023-37. PubMed ID: 7783134
    [No Abstract]   [Full Text] [Related]  

  • 2. Ribozymes: structure, characteristics and use as potential antiviral agents.
    Bartolomé J; Madejón A; Carreño V
    J Hepatol; 1995; 22(1 Suppl):57-64. PubMed ID: 7602079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribozymes: recent advances in the development of RNA tools.
    Puerta-Fernández E; Romero-López C; Barroso-delJesus A; Berzal-Herranz A
    FEMS Microbiol Rev; 2003 Apr; 27(1):75-97. PubMed ID: 12697343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hammerhead ribozymes: biochemical and chemical considerations.
    Goodchild J
    Curr Opin Mol Ther; 2000 Jun; 2(3):272-81. PubMed ID: 11249621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribozymes in gene therapy.
    Thompson JD; Macejak D; Couture L; Stinchcomb DT
    Nat Med; 1995 Mar; 1(3):277-8. PubMed ID: 7585047
    [No Abstract]   [Full Text] [Related]  

  • 6. Design of hairpin ribozymes for in vitro and cellular applications.
    Yu Q; Burke JM
    Methods Mol Biol; 1997; 74():161-9. PubMed ID: 9204431
    [No Abstract]   [Full Text] [Related]  

  • 7. Ribozymes as antiviral agents.
    Bartolomé J; Castillo I; Carreño V
    Minerva Med; 2004 Feb; 95(1):11-24. PubMed ID: 15041923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA as a catalyst: natural and designed ribozymes.
    von Ahsen U; Schroeder R
    Bioessays; 1993 May; 15(5):299-307. PubMed ID: 8343141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozymes: from mechanistic studies to applications in vivo.
    Ohkawa J; Koguma T; Kohda T; Taira K
    J Biochem; 1995 Aug; 118(2):251-8. PubMed ID: 8543555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of ribozymes to inhibit gene expression.
    Krüger M; Beger C; Wong-Staal F
    Methods Enzymol; 1999; 306():207-25. PubMed ID: 10432456
    [No Abstract]   [Full Text] [Related]  

  • 11. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
    Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
    Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-synthetically ligated ribozymes: an alternative approach to iterative solid-phase synthesis.
    Bellon L; Workman CT; Jarvis TC; Wincott FE
    Bioconjug Chem; 1997; 8(2):204-12. PubMed ID: 9095362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.
    Rossi JJ; Elkins D; Taylor N; Zaia J; Sullivan S; Deshler JO
    Antisense Res Dev; 1991; 1(3):285-8. PubMed ID: 1821650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro selection of hairpin ribozymes.
    Sargueil B; Burke JM
    Methods Mol Biol; 1997; 74():289-300. PubMed ID: 9204444
    [No Abstract]   [Full Text] [Related]  

  • 15. Minimized hammerhead ribozymes.
    McCall MJ; Hendry P; Lockett TJ
    Methods Mol Biol; 1997; 74():151-9. PubMed ID: 9204430
    [No Abstract]   [Full Text] [Related]  

  • 16. Design of hybridizing arms in hammerhead ribozymes.
    Hendry P; McCall MJ; Lockett TJ
    Methods Mol Biol; 1997; 74():253-64. PubMed ID: 9204440
    [No Abstract]   [Full Text] [Related]  

  • 17. Ribozymes: killing the messenger.
    Barinaga M
    Science; 1993 Dec; 262(5139):1512-4. PubMed ID: 8248799
    [No Abstract]   [Full Text] [Related]  

  • 18. Progress toward the structure and therapeutic use of the hairpin ribozyme.
    Earnshaw DJ; Gait MJ
    Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):403-11. PubMed ID: 9303192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and in vitro activity of ribozymes against mRNA of a rat membrane inhibitor of complement.
    Inui O; Tanaka T; Dohi N; Okada N; Okada H; Kikuchi Y
    Nucleic Acids Symp Ser; 1997; (37):223-4. PubMed ID: 9586080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient RNA ligation by reverse-joined hairpin ribozymes and engineering of twin ribozymes consisting of conventional and reverse-joined hairpin ribozyme units.
    Ivanov SA; Vauléon S; Müller S
    FEBS J; 2005 Sep; 272(17):4464-74. PubMed ID: 16128815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.